Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerXiu-Zhi Zhu(Shanghai Medical College of Fudan University), Zhonghua Wang(Shenyang Pharmaceutical University)Journal of Experimental & Clinical Cancer ResearchApril 8, 202110.1186/s13046-021-01930-wCited by 89SaveCiteExport RISWatch citationsRelated PapersThe prognostic and predictive potential of Ki-67 in triple-negative breast cancer|Scientific Reports|2020|185Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast Cancer|Research Square|2020|0